Nature Index officially published the ranking list of nature index in 2021. As a representative enterprise of "omics -driven new drug R&D", Precision Scientific is continuing to occupy the ranking list of the Chinese biomedical industry institution with high-quality scientific research output this year, ranking 5th, rising rapidly from 32nd in 2020.

"Precision Human HRD Assay (Reversible Termination Sequencing)" (Registration No. RPS/1075/2022) and "Precision Human BRCA1/BRCA2 Gene Mutation Detection Kit (Reversible Termination Sequencing)" (Registration No. RPS/133/2022) independently developed by Precision Scientific have passed the EU CE certification and obtained the EU market access qualification.

CAP-accredited Central Laboratories: Beijing Lab, Suzhou Lab.

Nov 2021, Signing ceremony with Roche Diagnostics for strategic partnership in NGS-based CDx research & development.

Mar 2021，Precision Scientific has reached a strategic cooperation agreement with Illumina and became IVD partner, in which both sides will carry out in-depth cooperation in the registration of cancer companion diagnostic products, and try the best to promote the registration and application of cancer companion diagnostic kits in China.

Jan 2021，Signing ceremony with AstraZeneca for strategic collaboration in NGS-based CDx development for Olaparib (Lynparza) in ovarian cancer.